Our findings revealed significantly higher circulating and local expression levels of survivin in bronchogenic carcinoma patients compared with in those with benign lung diseases, with non-significant differences in serum levels with regard to the histological types and in correlation with tumor stage. This evidence concerns the gene BIRC5 and neoplasm.